GSK3 inhibitors: Development and therapeutic potential

Philip Cohen; Michel Goedert

doi:10.1038/nrd1415

GSK3 inhibitors: Development and therapeutic potential

Philip Cohen, Michel Goedert

Research output: Contribution to journal › Review article › peer-review

710 Citations (Scopus)

Abstract

Glycogen synthase kinase-3 (GSK3) was initially identified more than two decades ago as an enzyme involved in the control of glycogen metabolism. In recent years it has been shown to have key roles in regulating a diverse range of cellular functions, which have prompted efforts to develop GSK3 inhibitors as therapeutics. Here, we describe the biology of GSK3 relevant to its potential as a target for diabetes and neurodegenerative diseases, and discuss progress in the development of GSK3 inhibitors.

Original language	English
Pages (from-to)	479-487
Number of pages	9
Journal	Nature Reviews Drug Discovery
Volume	3
Issue number	6
DOIs	https://doi.org/10.1038/nrd1415
Publication status	Published - 1 Jan 2004

ASJC Scopus subject areas

Pharmacology
Drug Discovery

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/nrd1415

Cite this

@article{fa34a3000562441abafbe3118a71ff5f,

title = "GSK3 inhibitors: Development and therapeutic potential",

abstract = "Glycogen synthase kinase-3 (GSK3) was initially identified more than two decades ago as an enzyme involved in the control of glycogen metabolism. In recent years it has been shown to have key roles in regulating a diverse range of cellular functions, which have prompted efforts to develop GSK3 inhibitors as therapeutics. Here, we describe the biology of GSK3 relevant to its potential as a target for diabetes and neurodegenerative diseases, and discuss progress in the development of GSK3 inhibitors.",

author = "Philip Cohen and Michel Goedert",

year = "2004",

month = jan,

day = "1",

doi = "10.1038/nrd1415",

language = "English",

volume = "3",

pages = "479--487",

journal = "Nature Reviews Drug Discovery",

issn = "1474-1776",

publisher = "Nature Research",

number = "6",

}

TY - JOUR

T1 - GSK3 inhibitors

T2 - Development and therapeutic potential

AU - Cohen, Philip

AU - Goedert, Michel

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Glycogen synthase kinase-3 (GSK3) was initially identified more than two decades ago as an enzyme involved in the control of glycogen metabolism. In recent years it has been shown to have key roles in regulating a diverse range of cellular functions, which have prompted efforts to develop GSK3 inhibitors as therapeutics. Here, we describe the biology of GSK3 relevant to its potential as a target for diabetes and neurodegenerative diseases, and discuss progress in the development of GSK3 inhibitors.

AB - Glycogen synthase kinase-3 (GSK3) was initially identified more than two decades ago as an enzyme involved in the control of glycogen metabolism. In recent years it has been shown to have key roles in regulating a diverse range of cellular functions, which have prompted efforts to develop GSK3 inhibitors as therapeutics. Here, we describe the biology of GSK3 relevant to its potential as a target for diabetes and neurodegenerative diseases, and discuss progress in the development of GSK3 inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=3042635178&partnerID=8YFLogxK

U2 - 10.1038/nrd1415

DO - 10.1038/nrd1415

M3 - Review article

C2 - 15173837

AN - SCOPUS:3042635178

SN - 1474-1776

VL - 3

SP - 479

EP - 487

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

IS - 6

ER -

GSK3 inhibitors: Development and therapeutic potential

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this